- Home
- HBIO vs NYC Comparison
HBIO vs NYC Comparison
Compare HBIO & NYC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | HBIO | NYC |
|---|---|---|
| Founded | 1901 | 2013 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Laboratory Analytical Instruments | Real Estate |
| Sector | Industrials | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 25.7M | 23.5M |
| IPO Year | 2000 | 2014 |
Fundamental Metrics
Financial Performance| Metric | HBIO | NYC |
|---|---|---|
| Price | $0.49 | $8.42 |
| Analyst Decision | Buy | |
| Analyst Count | 3 | 0 |
| Target Price | ★ $2.50 | N/A |
| AVG Volume (30 Days) | ★ 377.0K | 1.6K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $116,176,000.00 | N/A |
| Revenue This Year | N/A | $8.40 |
| Revenue Next Year | $7.80 | $1.62 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $0.28 | $7.03 |
| 52 Week High | $0.95 | $16.30 |
Technical Indicators
Market Signals| Indicator | HBIO | NYC |
|---|---|---|
| Relative Strength Index (RSI) | 33.59 | 45.68 |
| Support Level | $0.47 | $7.12 |
| Resistance Level | $0.55 | $10.33 |
| Average True Range (ATR) | 0.04 | 0.43 |
| MACD | -0.01 | -0.02 |
| Stochastic Oscillator | 6.33 | 19.98 |
Price Performance
Historical ComparisonAbout HBIO Harvard Bioscience Inc.
Harvard Bioscience Inc is a developer, manufacturer, and seller of technologies, specialized products and services that enable fundamental research, pharmaceutical and therapy discovery, bioproduction, and pre-clinical testing for drug development. Its primary focus is scientific instruments used to advance life sciences and research. With operations in North America, Europe and china it sells through a combination of direct and distribution channels to customers around the world. The product brands of the company include Harvard Apparatus, DSI, Buxco, Biochrom, BTX, Heka, Hugo Sachs, and Panlab. The majority of its revenue comes from the United States.
About NYC American Strategic Investment Co.
American Strategic Investment Co is an externally managed company that currently owns a portfolio of commercial real estate located within the five boroughs of New York City, majorly Manhattan. The Company's real estate assets consist of office properties and certain real estate assets that accompany office properties, including retail spaces and amenities.